Safety and Efficacy of Neoantigen-Based Personalized Immunotherapy as Consolidation Therapy After Standard Adjuvant Treatment in Resectable Stage III Colorectal Cancer or Non-Small Cell Lung Cancer

NCT07504484 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

6

Enrollment

OTHER

Sponsor class

Conditions

CRC (Colorectal Cancer)
Non Small Lung Cancer

Interventions

BIOLOGICAL: iNeo-Vac-P01

Sponsor

Ying Yuan, MD

Collaborators

[object Object]